

Activin Receptor Type 1 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A5483A26BEEEN.html>

Date: December 2019

Pages: 75

Price: US\$ 3,500.00 (Single User License)

ID: A5483A26BEEEN

Abstracts

Activin Receptor Type 1 - Pipeline Review, H2 2019

SUMMARY

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Activin Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Activin A receptor type I (ACVR1) is a protein is encoded by the ACVR1 gene. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. It acts as a receptor for activin. It is involved for left-right pattern formation during embryogenesis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Oncology, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones, Hematological Disorders, Metabolic Disorders and Toxicology which include indications Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Alport Syndrome, Anemia of Chronic

Disease, Chemotherapy Induced Anemia, Chronic Kidney Disease (Chronic Renal Failure), Kidney Fibrosis, Knee Osteoarthritis, Myelofibrosis, Myocardial Fibrosis, Obesity, Pediatric Diffuse Intrinsic Pontine Glioma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Solid Tumor, Thrombocythemia Myelofibrosis and Type 2 Diabetes.

Furthermore, this report also reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)

The report reviews Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics and enlists all their major and minor projects

The report assesses Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein

Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Overview

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Companies Involved in Therapeutics Development

BioCryst Pharmaceuticals Inc

Clementia Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Ember Therapeutics Inc (Inactive)

Keros Therapeutics Inc

La Jolla Pharmaceutical Company

M4K Pharma Inc

Oncodesign SA

Sierra Oncology Inc

Tolero Pharmaceuticals Inc

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Drug Profiles

Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description

Mechanism Of Action

R&D Progress

BCX-9250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCX-9499 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLU-782 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMP-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dipyridamole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KER-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

momelotinib dihydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ACVR1 for Pediatric Diffuse Intrinsic Pontine Glioma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0184 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Dormant Products

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Discontinued Products

Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Product Development Milestones

Featured News & Press Releases

Dec 07, 2019: Sierra Oncology reports decreased transfusion requirements for patients treated with Momelotinib directly compared to Ruxolitinib at ASH annual meeting

Dec 02, 2019: Sierra Oncology announces investor event to discuss Momelotinib data being reported at ASH

Nov 21, 2019: Sierra Oncology initiates study of momelotinib in myelofibrosis

Nov 06, 2019: Sierra Oncology to report new analyses supporting Momelotinib's anemia benefits at ASH 2019

Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva

Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)

Jun 27, 2019: Sierra Oncology launches campaign exploring non-dilutive strategic options to support development of its DDR Assets

Jun 07, 2019: FDA grants fast-track designation to bone marrow cancer drug

Jun 04, 2019: Sierra announces FDA regulatory clarity for Momelotinib & design of the MOMENTUM phase 3 clinical trial

May 28, 2019: Sierra Oncology to Present Momelotinib Overview at the Jefferies Global Healthcare Conference in New York

Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782

Feb 27, 2019: Tolero Pharmaceuticals to present new data evaluating investigational agent TP-0184 at AACR Annual Meeting 2019

Dec 03, 2018: Sierra Oncology reports robust transfusion independence rates in transfusion dependent myelofibrosis patients treated with momelotinib

Nov 27, 2018: Sierra Oncology to host analyst call highlighting clinical data on Momelotinib's anemia benefit

Nov 01, 2018: Sierra Oncology to report clinical data at ASH 2018 from translational biology study of Momelotinib in transfusion dependent patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
Pipeline by Clementia Pharmaceuticals Inc, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
Pipeline by Keros Therapeutics Inc, H2 2019
Pipeline by La Jolla Pharmaceutical Company, H2 2019
Pipeline by M4K Pharma Inc, H2 2019
Pipeline by Oncodesign SA, H2 2019
Pipeline by Sierra Oncology Inc, H2 2019
Pipeline by Tolero Pharmaceuticals Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Ember Therapeutics Inc (Inactive)
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
M4K Pharma Inc
Oncodesign SA
Sierra Oncology Inc
Tolero Pharmaceuticals Inc

I would like to order

Product name: Activin Receptor Type 1 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A5483A26BEEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A5483A26BEEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970